Press Releases - Emmaus Medical, Inc.

Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi ArabiaJanuary 29, 2025

Initial One-Year Exclusivity Period Will Be Extended to Three Years if Endari is Approved for Marketing

Emmaus Life Sciences Reports Improved Quarterly Financial ResultsNovember 19, 2024

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.

Emmaus Life Sciences Reports Quarterly Financial ResultsSeptember 10, 2024

Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.

Emmaus Life Sciences Announces Willis C. Lee as Chief Executive OfficerJuly 23, 2024

Emmaus Life Sciences, Inc., announced that Willis C. Lee has been appointed as Chief Executive Officer.

Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance ProgramJuly 12, 2024

Emmaus Life Sciences, Inc., today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.